• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

筛查性乳房 X 光摄影中导管原位癌检测的变化:国际癌症筛查网络内的调查。

Variation in detection of ductal carcinoma in situ during screening mammography: a survey within the International Cancer Screening Network.

机构信息

Department of Public Health, University of Copenhagen, Copenhagen, Denmark.

CPO Piemonte, AOU San Giovanni Battista, Torino, Italy.

出版信息

Eur J Cancer. 2014 Jan;50(1):185-92. doi: 10.1016/j.ejca.2013.08.013. Epub 2013 Sep 13.

DOI:10.1016/j.ejca.2013.08.013
PMID:24041876
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3874251/
Abstract

BACKGROUND

There is concern about detection of ductal carcinoma in situ (DCIS) in screening mammography. DCIS accounts for a substantial proportion of screen-detected lesions but its effect on breast cancer mortality is debated. The International Cancer Screening Network conducted a comparative analysis to determine variation in DCIS detection.

PATIENTS AND METHODS

Data were collected during 2004-2008 on number of screening examinations, detected breast cancers, DCIS cases and Globocan 2008 breast cancer incidence rates derived from national or regional cancer registers. We calculated screen-detection rates for breast cancers and DCIS.

RESULTS

Data were obtained from 15 screening settings in 12 countries; 7,176,050 screening examinations; 29,605 breast cancers and 5324 DCIS cases. The ratio between highest and lowest breast cancer incidence was 2.88 (95% confidence interval (CI) 2.76-3.00); 2.97 (95% CI 2.51-3.51) for detection of breast cancer; and 3.49 (95% CI 2.70-4.51) for detection of DCIS.

CONCLUSIONS

Considerable international variation was found in DCIS detection. This variation could not be fully explained by variation in incidence nor in breast cancer detection rates. It suggests the potential for wide discrepancies in management of DCIS resulting in overtreatment of indolent DCIS or undertreatment of potentially curable disease. Comprehensive cancer registration is needed to monitor DCIS detection. Efforts to understand discrepancies and standardise management may improve care.

摘要

背景

在筛查性乳房 X 光检查中,人们对导管原位癌(DCIS)的检测存在担忧。DCIS 占筛查出的病变的很大一部分,但它对乳腺癌死亡率的影响仍存在争议。国际癌症筛查网络进行了一项比较分析,以确定 DCIS 检测的差异。

患者和方法

2004 年至 2008 年期间,我们收集了筛查检查次数、检出的乳腺癌、DCIS 病例以及来自国家或地区癌症登记处的 2008 年全球癌症发病率数据。我们计算了乳腺癌和 DCIS 的筛查检出率。

结果

我们从 12 个国家的 15 个筛查机构获得了数据,涵盖了 7176050 次筛查检查、29605 例乳腺癌和 5324 例 DCIS 病例。乳腺癌发病率最高和最低的比值为 2.88(95%置信区间 2.76-3.00);乳腺癌检出率为 2.97(95%置信区间 2.51-3.51);DCIS 检出率为 3.49(95%置信区间 2.70-4.51)。

结论

我们发现 DCIS 的检测存在相当大的国际差异。这种差异不能完全用发病率或乳腺癌检出率的差异来解释。这表明,在 DCIS 的管理上可能存在广泛的差异,导致对惰性 DCIS 的过度治疗或对可能可治愈的疾病的治疗不足。全面的癌症登记是监测 DCIS 检测的必要手段。努力了解差异并标准化管理可能会改善护理。

相似文献

1
Variation in detection of ductal carcinoma in situ during screening mammography: a survey within the International Cancer Screening Network.筛查性乳房 X 光摄影中导管原位癌检测的变化:国际癌症筛查网络内的调查。
Eur J Cancer. 2014 Jan;50(1):185-92. doi: 10.1016/j.ejca.2013.08.013. Epub 2013 Sep 13.
2
Trends in detection of invasive cancer and ductal carcinoma in situ at biennial screening mammography in Spain: a retrospective cohort study.西班牙两年一次的筛查性乳房 X 光检查中浸润性癌和导管原位癌检出率的变化趋势:一项回顾性队列研究。
PLoS One. 2013 Dec 23;8(12):e83121. doi: 10.1371/journal.pone.0083121. eCollection 2013.
3
Screen detection of ductal carcinoma in situ and subsequent incidence of invasive interval breast cancers: a retrospective population-based study.导管原位癌的筛查检测及随后发生的浸润性间隔期乳腺癌:一项基于人群的回顾性研究。
Lancet Oncol. 2016 Jan;17(1):109-14. doi: 10.1016/S1470-2045(15)00446-5. Epub 2015 Dec 5.
4
Detection of ductal carcinoma in situ in women undergoing screening mammography.在接受乳腺钼靶筛查的女性中检测导管原位癌。
J Natl Cancer Inst. 2002 Oct 16;94(20):1546-54. doi: 10.1093/jnci/94.20.1546.
5
The contribution of mammography screening to breast cancer incidence trends in the United States: an updated age-period-cohort model.乳腺X线筛查对美国乳腺癌发病趋势的贡献:一个更新的年龄-时期-队列模型
Cancer Epidemiol Biomarkers Prev. 2015 Jun;24(6):905-12. doi: 10.1158/1055-9965.EPI-14-1286. Epub 2015 Mar 18.
6
The method of detection of ductal carcinoma in situ has no therapeutic implications: results of a population-based cohort study.原位导管癌的检测方法并无治疗意义:一项基于人群的队列研究结果
Breast Cancer Res. 2017 Mar 9;19(1):26. doi: 10.1186/s13058-017-0819-4.
7
The mammography screening detection of ductal carcinoma in situ and invasive breast cancer according to women's characteristics: is it the same?根据女性特征的乳腺 X 线筛查对导管原位癌和浸润性乳腺癌的检出:是否相同?
Breast Cancer Res Treat. 2019 Apr;174(2):525-535. doi: 10.1007/s10549-018-05095-7. Epub 2018 Dec 18.
8
International variation in management of screen-detected ductal carcinoma in situ of the breast.乳腺筛查发现的导管原位癌管理的国际差异。
Eur J Cancer. 2014 Oct;50(15):2695-704. doi: 10.1016/j.ejca.2014.07.019. Epub 2014 Aug 19.
9
Mode of detection and secular time for ductal carcinoma in situ.导管原位癌的检测方式与长期时间
J Natl Cancer Inst Monogr. 2010;2010(41):142-4. doi: 10.1093/jncimonographs/lgq028.
10
Rapid increase in incidence of breast ductal carcinoma in situ in Girona, Spain 1983-2007.西班牙赫罗纳地区 1983-2007 年乳腺导管原位癌发病率的快速增长。
Breast. 2012 Oct;21(5):646-51. doi: 10.1016/j.breast.2012.01.014. Epub 2012 Feb 14.

引用本文的文献

1
Mammography screening and incidence of ductal carcinoma in situ of the breast in Italy: an age-period-cohort analysis.意大利乳腺钼靶筛查与乳腺导管原位癌发病率:年龄-时期-队列分析
Int J Epidemiol. 2025 Jun 11;54(4). doi: 10.1093/ije/dyaf102.
2
Incidence trends of ductal carcinoma in situ in New Zealand women between 1999 and 2022.1999年至2022年间新西兰女性原位导管癌的发病趋势。
Breast Cancer Res Treat. 2025 Apr;210(2):439-449. doi: 10.1007/s10549-024-07582-6. Epub 2025 Jan 25.
3
Use of beta-blockers in patients with ductal carcinoma in situ and risk of invasive breast cancer recurrence: a Swedish retrospective cohort study.

本文引用的文献

1
Comparative effectiveness of digital versus film-screen mammography in community practice in the United States: a cohort study.美国社区实践中数字与屏片式乳腺 X 线摄影的比较效果:一项队列研究。
Ann Intern Med. 2011 Oct 18;155(8):493-502. doi: 10.7326/0003-4819-155-8-201110180-00005.
2
Biological Markers in DCIS and Risk of Breast Recurrence: A Systematic Review.DCIS 中的生物学标志物与乳腺癌复发风险:系统评价。
J Cancer. 2011 May 1;2:232-61. doi: 10.7150/jca.2.232.
3
Characterizing the impact of 25 years of DCIS treatment.描述 25 年 DCIS 治疗的影响。
β受体阻滞剂在导管原位癌患者中的应用与浸润性乳腺癌复发风险:一项瑞典回顾性队列研究。
Breast Cancer Res Treat. 2024 Sep;207(2):293-299. doi: 10.1007/s10549-024-07358-y. Epub 2024 May 19.
4
Subtypes of high-grade breast ductal carcinoma in situ (DCIS): incidence and potential clinical impact.高级别乳腺导管原位癌(DCIS)的亚型:发生率和潜在的临床影响。
Breast Cancer Res Treat. 2023 Sep;201(2):329-338. doi: 10.1007/s10549-023-07016-9. Epub 2023 Jul 15.
5
Non-progressive breast carcinomas detected at mammography screening: a population study.乳腺 X 线筛查检出的非进展性乳腺癌:一项人群研究。
Breast Cancer Res. 2023 Jul 4;25(1):80. doi: 10.1186/s13058-023-01682-9.
6
Ductal Carcinoma in Situ: A Detailed Review of Current Practices.导管原位癌:当前诊疗实践的详细综述
Cureus. 2023 Apr 21;15(4):e37932. doi: 10.7759/cureus.37932. eCollection 2023 Apr.
7
Treatment of Ductal Carcinoma in situ: A Register-Based Study of Norwegian Women Diagnosed between 1995 and 2018.导管原位癌的治疗:一项基于登记的对1995年至2018年间确诊的挪威女性的研究。
Breast Care (Basel). 2022 Oct;17(5):486-494. doi: 10.1159/000524564. Epub 2022 Apr 21.
8
Magnetically Guided Localization Using a Guiding-Marker System and a Handheld Magnetic Probe for Nonpalpable Breast Lesions: A Multicenter Feasibility Study in Japan.使用引导标记系统和手持式磁探针进行磁引导定位以诊断不可触及乳腺病变:日本多中心可行性研究
Cancers (Basel). 2021 Jun 11;13(12):2923. doi: 10.3390/cancers13122923.
9
Comparison of the ductal carcinoma in situ between White Americans and Chinese Americans.白种美国人和华裔美国人群体中导管原位癌的比较。
Medicine (Baltimore). 2021 Jan 22;100(3):e24136. doi: 10.1097/MD.0000000000024136.
10
Multiple Microinvasion Foci in Ductal Carcinoma Is Associated With an Increased Risk of Recurrence and Worse Survival Outcome.导管癌中的多个微浸润灶与复发风险增加及更差的生存结果相关。
Front Oncol. 2020 Dec 3;10:607502. doi: 10.3389/fonc.2020.607502. eCollection 2020.
Breast Cancer Res Treat. 2011 Aug;129(1):165-73. doi: 10.1007/s10549-011-1430-5. Epub 2011 Mar 9.
4
Balancing sensitivity and specificity: sixteen year's of experience from the mammography screening programme in Copenhagen, Denmark.平衡敏感性和特异性:丹麦哥本哈根乳腺摄影筛查项目 16 年的经验。
Cancer Epidemiol. 2011 Oct;35(5):393-8. doi: 10.1016/j.canep.2010.12.001. Epub 2011 Jan 15.
5
Trends in incidence of ductal carcinoma in situ: the effect of a population-based screening programme.导管原位癌发病率趋势:基于人群的筛查计划的影响。
Breast. 2010 Dec;19(6):499-505. doi: 10.1016/j.breast.2010.05.014. Epub 2010 Jun 17.
6
Choosing treatment for patients with ductal carcinoma in situ: fine tuning the University of Southern California/Van Nuys Prognostic Index.为导管原位癌患者选择治疗方法:对南加州大学/凡奈斯预后指数进行微调。
J Natl Cancer Inst Monogr. 2010;2010(41):193-6. doi: 10.1093/jncimonographs/lgq040.
7
Reproducibility of three classification systems of ductal carcinoma in situ of the breast using a web-based survey.基于网络调查的三种乳腺导管原位癌分类系统的可重复性研究。
Pathol Res Pract. 2010 Oct 15;206(10):705-11. doi: 10.1016/j.prp.2010.06.004. Epub 2010 Jul 21.
8
Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis.初始导管原位癌诊断后生物标志物表达与后续肿瘤风险。
J Natl Cancer Inst. 2010 May 5;102(9):627-37. doi: 10.1093/jnci/djq101. Epub 2010 Apr 28.
9
National Institutes of Health State-of-the-Science Conference statement: Diagnosis and Management of Ductal Carcinoma In Situ September 22-24, 2009.美国国立卫生研究院科学会议声明:导管原位癌的诊断和治疗,2009 年 9 月 22 日至 24 日。
J Natl Cancer Inst. 2010 Feb 3;102(3):161-9. doi: 10.1093/jnci/djp485. Epub 2010 Jan 13.
10
Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes.乳腺导管原位癌:发病率、治疗和结局的系统评价。
J Natl Cancer Inst. 2010 Feb 3;102(3):170-8. doi: 10.1093/jnci/djp482. Epub 2010 Jan 13.